FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.
What happened
FDA inspected the company's drug manufacturing facility in South El Monte, California, from December 9 to 19, 2025. Investigators found environmental monitoring plates in and next to the ISO 5 aseptic filling area (the cleanest area, where sterile product is exposed) with too-many-to-count bacterial growth and insect larvae, and the company released the epinephrine injection lot made that day. FDA also found the company's investigations, aseptic line design, and a water storage tank with dark-colored buildup to be inadequate; after an FDA teleconference on March 26, 2026, the company voluntarily recalled epinephrine injection USP 0.1 mg/mL lot EA038A5 on April 1, 2026 for lack of sterility assurance.
What FDA found
The company did not properly investigate contamination findings and released a batch even though monitoring plates in the sterile filling area showed heavy bacterial growth and insect larvae.
21 CFR 211.192The aseptic filling lines are not built or controlled to prevent contamination: an operator stands inside the cleanest zone and manually cuts open and scoops stoppers, that area was not monitored, and the airflow (smoke) studies were not done properly.
21 CFR 211.42(c)(10) and 21 CFR 211.113(b)The water system's storage tank, which also feeds cleaning, was coated inside with dark-colored buildup, had been patched with sealant, and used threaded taped connections instead of sanitary fittings.
21 CFR 211.63The quality unit allowed release of a lot made under contaminated conditions instead of rejecting it, so it did not use its authority to protect product quality.
The company relied on passing sterility tests to justify release, although a sterility test alone cannot show that every unit is sterile.
What FDA wants
FDA tells the company to correct the violations promptly and to reply in writing within 15 working days, including third-party assessments and remediation plans for investigations, corrective actions, pest control, aseptic operations and the water system, plus a risk review of batches still within expiry. If corrective actions cannot be finished in that time, the company must explain the delay and give a schedule.
Who should pay attention
- hospital and clinic buyers of sterile injectables, including epinephrine
- distributors and repackagers of this firm's sterile drug products
- quality teams at other firms running aseptic filling lines or buying APIs from this site
This is a summary. Read the original letter on fda.gov.